Brompheniramine, pseudoephedrine and dextromethorphan

R06AB01(WHO) AU:S4(Prescription only) /Schedule 4; Schedule 3; Schedule 2; Appendix K, clause 1US:℞-only/OTC (R/S)-3-(4-Bromophenyl)-N,N-dimethyl-3-pyridin-2-yl-propan-1-amine 86-22-6Y 6834 7133 DB00835Y 6573Y H57G17P2FN D07543Y CHEBI:3183Y ChEMBL811Y DTXSID5022691 Interactive image Brc1ccc(cc1)C(c2ncccc2)CCN(C)C InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3YKey:ZDIGNSYAACHWNL-UHFFFAOYSA-NY Brompheniramine, sold under the brand nameDimetappamong others, is a first-generationantihistaminedrug of thepropylamine(alkylamine) class.It is indicated for the treatment of the symptoms of thecommon coldandallergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing. Like the other first-generation drugs of its class, it is considered asedatingantihistamine. It was patented in 1948 and came into medical use in 1955.In 2023, the combination withdextromethorphanandpseudoephedrinewas the 281st most commonly prescribed medication in the United States, with more than 700,000 prescriptions.